Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 8.94% and Operating profit at -8.63% over the last 5 years
- INTEREST(HY) At CNY 32.74 MM has Grown at 24.49%
- OPERATING CASH FLOW(Y) Lowest at CNY 1,352.55 MM
- INTEREST COVERAGE RATIO(Q) Lowest at 2,010.56
2
With ROE of 7.92%, it has a very attractive valuation with a 0.61 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,061 Million (Large Cap)
8.00
NA
5.23%
-0.13
7.92%
0.61
Revenue and Profits:
Net Sales:
2,667 Million
(Quarterly Results - Jun 2025)
Net Profit:
256 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.29%
0%
-1.29%
6 Months
-27.4%
0%
-27.4%
1 Year
7.73%
0%
7.73%
2 Years
2.33%
0%
2.33%
3 Years
-49.33%
0%
-49.33%
4 Years
-53.1%
0%
-53.1%
5 Years
-63.69%
0%
-63.69%
Winner Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.94%
EBIT Growth (5y)
-8.63%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.65
Tax Ratio
20.25%
Dividend Payout Ratio
54.51%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
43.99%
ROE (avg)
14.21%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.61
EV to EBIT
5.76
EV to EBITDA
3.38
EV to Capital Employed
0.55
EV to Sales
0.54
PEG Ratio
0.04
Dividend Yield
5.23%
ROCE (Latest)
9.60%
ROE (Latest)
7.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,666.90
2,582.10
3.28%
Operating Profit (PBDIT) excl Other Income
440.60
482.10
-8.61%
Interest
16.70
15.50
7.74%
Exceptional Items
5.90
2.20
168.18%
Consolidate Net Profit
256.40
261.70
-2.03%
Operating Profit Margin (Excl OI)
101.60%
121.00%
-1.94%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 3.28% vs -10.34% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -2.03% vs 69.39% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8,897.90
8,118.60
9.60%
Operating Profit (PBDIT) excl Other Income
1,409.20
1,247.40
12.97%
Interest
58.10
64.40
-9.78%
Exceptional Items
-94.90
-157.00
39.55%
Consolidate Net Profit
740.70
628.50
17.85%
Operating Profit Margin (Excl OI)
86.90%
80.40%
0.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.60% vs -27.86% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.85% vs -62.46% in Dec 2023
About Winner Medical Co., Ltd. 
Winner Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






